Ono Pharmaceutical (OTCMKTS:OPHLF) Shares Gap Up - Should You Buy?

Key Points

• Ono Pharmaceutical's stock opened at $12.58 after previously closing at $10.95, reflecting a significant pre-trading gap up of approximately 15.0%.
• The company reported earnings per share (EPS) of $0.26 for the latest quarter, missing analysts' estimates of $0.34, despite revenues of $886.27 million exceeding expectations.
• Ono Pharmaceutical maintains a strong financial position with a debt-to-equity ratio of 0.13 and current and quick ratios of 3.07 and 2.56, respectively.

Ono Pharmaceutical Co. (OTCMKTS:OPHLF - Get Free Report)'s stock price gapped up prior to trading on Monday . The stock had previously closed at $10.95, but opened at $12.58. Ono Pharmaceutical shares last traded at $12.58, with a volume of 353 shares changing hands.

Ono Pharmaceutical Price Performance

The firm has a market capitalization of $5.74 billion, a price-to-earnings ratio of 19.71 and a beta of 0.51. The firm has a fifty day moving average price of $10.69 and a 200 day moving average price of $10.75. The company has a current ratio of 3.07, a quick ratio of 2.56 and a debt-to-equity ratio of 0.13.

Ono Pharmaceutical (OTCMKTS:OPHLF - Get Free Report) last released its quarterly earnings results on Monday, August 4th. The company reported $0.26 earnings per share for the quarter, missing analysts' consensus estimates of $0.34 by ($0.08). The business had revenue of $886.27 million for the quarter, compared to analyst estimates of $827.29 million. Ono Pharmaceutical had a net margin of 8.75% and a return on equity of 5.49%.

Ono Pharmaceutical Company Profile

Ono Pharmaceutical Co, Ltd., together with its subsidiaries, produces, purchases, and sells pharmaceuticals and diagnostic reagents worldwide. It offers Opdivo Intravenous Infusion and Kyprolis Intravenous Injection for malignant tumors; Emend capsules/Proemend intravenous injections for chemotherapy-induced nausea and vomiting; Demser capsules for the symptoms in patients with pheochromocytoma; and Mektovi, Velexbru, and Braftovi capsules for malignant tumors, as well as ADLUMIZ tablets for cancer cachexia.